NICE Single Technology Appraisal Guidance No
Bivalirudin for the treatment of ST-segment-elevation
This NICE guidance was published on 27 July
2011. The web reference for the appraisal and other
related documents is: www.nice.org.uk/TA230
NHSScotland should note
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (638/10) on
this medication for this indication in September 2010. This stated
Bivalirudin (Angiox) is
accepted for use within NHS Scotland as an anticoagulant in adult
patients undergoing percutaneous coronary intervention (PCI),
including patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary PCI. Bivalirudin should be administered
with aspirin and clopidogrel. Its use is restricted topatients who
would have been considered for treatment with heparin in
combination with a glycoprotein IIb/IIIa inhibitor. It should not
be used as an alternative to heparin alone.
Access the advice of SMC
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
Published Date: 27 July 2011